

Study of Additional Chromosomal Abnormalities in Young Adult Egyptian Chronic Myeloid Leukemia Patients

Thesis

**Submitted for Partial Fulfillment of M.D of
Clinical Hematology**

Presented by
Asmaa Mohammed Elsayed Eissa
(M.B., B.Ch. M.Sc.)

Under Supervision of
Prof. Dr. Mohamed Osman Azzazi
Professor of Internal Medicine and Hematology
Faculty of Medicine – Ain Shams University

Dr. Mohamed Mahmoud Moussa
Professor of Internal Medicine and Hematology
Faculty of Medicine – Ain Shams University

Dr. Mohamed Tarif Mohamed Hamza
Assistant Professor of Clinical Pathology
Faculty of Medicine – Ain Shams University

Dr. Amro Mohamed Sedky El-Ghammaz
Assistant Professor of Internal Medicine and Hematology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2018**



Acknowledgement

First of all, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

My profound thanks and deep appreciation to **Prof. Dr. Mohamed Osman Azzazi**, Professor of Internal Medicine and Hematology, Faculty of Medicine – Ain Shams University, for his great support and advice, his valuable remarks that gave me the confidence and encouragement to fulfill this work,

I am deeply grateful to **Dr. Mohamed Mahmoud Moussa**, Professor of Internal Medicine and Hematology, Faculty of Medicine – Ain Shams University, for adding a lot to this work by his experience and for his keen supervision.

I am also thankful to **Dr. Mohamed Tarif Mohamed Hamza**, Assistant Professor of Clinical Pathology, Faculty of Medicine – Ain Shams University for his valuable supervision, co-operation and direction that extended throughout this work,

I would like to direct my special thanks to **Dr. Amro Mohamed Sedky El-Ghammaz**, Assistant Professor of Internal Medicine and Hematology, Faculty of Medicine – Ain Shams University, for his invaluable help, fruitful advice, continuous support offered to me and guidance step by step till this essay finished.

I am extremely sincere to **my family** who stood beside me throughout this work giving me their support.

Words fail to express my love, respect and appreciation to **my husband** for his unlimited help and support.

Lastly, all the love to **my dear daughter** for being patient, understanding and cheerful throughout this work,

Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.

Asmaa Mohammed Elsayed Eissa

List of Contents

	Page
Acknowledgment	--
List of Abbreviations	i
List of Figures	ii
List of Tables	v
Introduction	1
Aim of The Work	3
Review of Literature	4
Chapter 1 : Chronic Myeloid Leukemia	4
Chapter 2 : Management of the Disease	26
Chapter 3 : Monitoring response and resistance to treatment	53
Chapter 4 : Additional chromosomal anomalies	72
Patients and Methods	90
Results	100
Discussion	116
Summary and Conclusion	124
Recommendations	128
References	129
Arabic Summary	--

List of Abbreviations

ABC.....	ATP Binding Cassette
ABL.....	Abelson protonocogene
ACAs	Additional chromosomal anomalies
aCML.....	Atypical CML
AGP1	Acid glycoprotein-1
ALL.....	Acute lymphoblastic leukemia
ALLG.....	Australasian Leukemia and Lymphoma
allo SCT	Allogeneic stem cell transplantation
AML.....	Acute myeloid leukemia
AP.....	Accelerated phase
ARG	Abl-related gene
ASAP	as soon as possible
ATP	Adenosine triphosphate
AYA	Adolescent and young adult
Bcl-xL	B-cell lymphoma-extra large
BCR-ABL....	Break point cluster region - Ableson proto-oncogene
BP.....	Blastic phase
CBL.....	Casitas B lineage c lymphoma protein
CCR.....	Complete cytogenetic response
CE.....	Clonal evolution
CHR.....	Complete hematologic response
CMR	Complete Molecular Response
CML	Chronic myeloid leukemia
CP.....	Chronic phase
CLL.....	Chronic lymphocytic leukemia
CRKl.....	CRK Like Proto-Oncogene, Adaptor Protein
CYP.....	Cytochromes P
CTL	Cytotoxic T cell
DADI	Dasatinib Discontinuation
DAPI.....	4',6-diamidino-2-phenylindole
DCs	Dendritic cells
Der	Derivatinve
DISC.....	Death-inducing signaling complex
DNA	Deoxyribonucleic acid
dNTPs	Deoxynucleotide triphosphates
DW.....	Distilled water

List of Abbreviations (Cont.)

EFS.....	Event free survival
ELN.....	European leukemia net
EMR.....	Early molecular response
Erk.....	Extracellular signal–regulated kinases
EVI1.....	Eco- tropic virus integration-1
FBS.....	Fetal bovine serum (FBS)..
<i>FCS</i>	fetal calf serum
FDA.....	Food & drug administration
FISH.....	Flourescene insitu hybridization
FGFR.....	Fibroblast Growth Factor
Grb.....	Growth factor receptor-bound protein
GTP.....	Guanosine-5'-triphosphate
HLA.....	Human leukocyte antigen
i17.....	Isochromosome 17
IBMT.....	International Bone marrow Transplantation
ICSBP.....	interferon consensus sequence-binding protein
IRIS.....	International ranomised study of interferone
IFN δ	Interferon δ
Inv.....	Inversion
Jak-STAT	Janus kinase/signal transducers and activators of transcription
Kb.....	Kilobase
KD.....	Kinase domain
KDa.....	Kilo Dalton
LSI.....	Locus Specific Identifier
MAPK.....	mitogen-activated protein kinase pathway
M-bcr.....	Major breakpoint cluster region
μ -bcr.....	Micro breakpoint cluster region
m-bcr.....	Minor breakpoint cluster region
Mek1/Mek2..	Dual-specificity protein kinases
MDS/MPN...	Myelodysplastic/myeloproliferative neoplasms
mRNA.....	Messenger Rna
M7S.....	Monosomy 7 syndrome
M MLV.....	Moloney murine leukemia virus
MMR.....	Major: Molecular response
MPO.....	Myeloperoxidase
MYC.....	Oncogene

List of Abbreviations (Cont.)

NCCN	National comprehensive cancer network
NP-40	Nonyl phenoxypolyethoxylethanol
OCT-1	Organic cation transporter-1
OS	Overall survival
PAH	Pulmonary arterial hypertension
PBS	Phosphate Buffered Saline
PCR	Polymerase chain reaction
PFS	Progression free survival
PGDFR	Platelet derived growth factor receptor
Ph	Philadelphia chromosome
PI3	Phosphatidyl Inositol-3
PNET	Primitive neuroectodermal tumors
RAF	Rapidly accelerated fibroblastoma
RAS	Rat sarcoma
RAS-MAPK	RAS mitogen activated protein oncogene
RB1	Retinoblastma protein
RBP	Receptor bound protein
RPMI	Roswell Park Memorial Institute
Rpm	Round per minute
RT	Reverse transcriptase
RT-PCR	Reverse Transcriptase Polymerase chain reaction
SEER	Surveillance epidemiology end results
Shc	Sirohydrochlorin
Shh	Sonic Hedgehog
SK	Sphingosine kinase
SPSS	Statistical program for social science
SRC	Protooncogene for sarcoma
SFKs	SRC family kinases
SNP	Single nucleotide polymorphism
SSC	Saline Sodium Citrate
STAT	Signal transducers & activators of transcription
STIM	stopping imatinib
TFR	Treatment-free remission
T h	Helper T
TKI	Tyrosine kinase inhibitor

List of Abbreviations (Cont.)

UGT1A1	Uridinediphosphateglucuronosyltransferase Family 1 Member A1
VEGF.....	Vascular Endothelial Growth Factor
WBC.....	White Blood Cell
WHO.....	World Health Organization

List of Figures

Fig.	Title	Page
1	Estimated total ph+ CML patients world wide.	5
2	Philadelphia chromosome. A piece of chromosome 9 and a piece of chromosome 22 break off and trade places.	8
3	The translocation of t (9;22) (q34;q11) in CML.	10
4	Structure of the p210 BCR ABL fusion protein and mechanisms of leukemogenesis.	11
5	Signaling Pathways of p210 <i>BCR ABL</i> .	14
6	Role of BCR-ABL in disease progression.	21
7	Schedule of chronic myeloid leukemia treatment development.	27
8	Mechanism of Imatinib-Mediated Inhibition of BCR-ABL.	33
9	Distribution of the mutations with respect to the main regions of the Bcr-abl kinase domain.	67
10	De novo synthases and metabolism of ceramide in sphingomyelin pathway.	68
11	The balance between sphingolipids determines the cell fate mechanism (cell survival or cell death).	70
12	The i (17q) formation.	77
13	Map of all the amino acid substitutions in the Bcr-Abl KD.	85
14	Follow up time for cases .	100
15	The distribution of additional chromosomal anomalies in the studied patients.	103
16	Hematological response.	106
17a	Time to molecular response for all patients.	112

Fig.	Title	Page
17b	Time to molecular response in patients with ACAS positive and negative.	113
18	Kaplan meir curve for ACAS at diagnosis.	114
19	Kaplan Meir curve for ACAS during treatment.	114
20	Kaplan Meir curve for ch 17 during treatment.	115

List of Tables

Table	Title	Page
1	Criteria for accelerated phase according to 3 frequently used classifications.	19
2	List of the criteria for the definition of AP and BP, as recommended by ELN and by the World Health Organization.	20
3	US FDA-Approved BCR-ABL1 TKIs.	31
4	Side Effects for BCR-ABL Inhibitors.	40
5	Role and Timing of allo HSCT.	43
6	Recommendations for monitoring response to TKI therapy and mutational analysis.	53
7	The definition of the hematologic, cytogenetic and molecular responses in CML.	55
8a	Definition of the response to TKIs (any TKI) as first-line treatment.	57
8b	Definitions of the response to second-line therapy incase of failure of imatinib.	57
9	Sokal, Hasford, and EUTOS Systems.	59
10	Summary of the cases in which BCR-ABL KD mutation analysis is recommended.	87
11	Summary of the most appropriate alternative therapeutic options based on the BCR-ABL KD mutation status.	89
12	Patients characteristics according to ACAs.	102
13	The correlation between sex and other baseline parameters.	103
14	Patients characteristics according to ACAs.	105
15	Hematological response.	106
16	Molecular response.	107
17	The ACAS during treatment.	107

Table	Title	Page
18	Characters of patients who didn't achieve molecular response according ACAS during treatment.	108
19	Ch17 with age.	109
20	Ch17 with gender.	109
21	ACAS and Hematologic Response.	109
22	ACAS and Molecular_Response	110
23	ACAS during treatment and Hematologic Response.	110
24	ACAS during treatment and Molecular_Response.	111
25	Treatment and ch17abnormalities.	111
26	Ch 17 abnormalities and Molecular Response.	112

INTRODUCTION

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of Philadelphia chromosome which is the cytogenetic hallmark of chronic myeloid leukemia. It is characterized by a reciprocal translocation $t(9;22)(q34;q11)$. The resulting molecular event is the creation of the BCR/ ABL fusion gene (*Kaaren et al., 2009*).

CML has a worldwide incidence of 1-1.5 cases per 100,000 inhabitants. CML constitutes 15-20% of all leukemias. The median age at diagnosis is 40-60 years, and although it is rare below 20 years, all age groups can be affected, CML has a slight male predominance (*Fletcher et al., 2011*).

CML incidence rates in western countries vary from 0.6 to 2.0 cases per 100,000 inhabitants (*Azzazi and Mattar, 2013*).

The disease is characterized by three phases of the disease namely chronic phase (CP), acceleration phase (AP) and blastic crisis (BC). According to the European Leukemia Net (ELN), the criteria for blastic crisis CML are percentage of blasts plus promyelocytes in peripheral blood or bone marrow $\geq 20\%$, progressive splenomegaly, thrombocytopenia ($< 100 \times 10^3/\mu\text{L}$) unrelated to therapy, and karyotypic evolution (*Baccarani et al., 2013*).

Recent interest in additional chromosomal abnormalities (ACAs) in chronic myeloid leukemic patients is now gaining more importance particularly in progressive disease (*Azzazi and Mattar, 2013*).

The appearance of these ACAs during treatment is commonly known as clonal evolution (CE) and seems to

play an important role in imatinib mesylate resistance; The World Health Organization (WHO) classification suggests that those patients showing ACAs emerging during treatment should be considered in accelerated phase (AP). The European Leukemia Net (ELN) recommendations suggest that the presence of ACAs at diagnosis may represent a "warning" feature, requiring careful monitoring of the patient (*Luatti et al., 2012*).

In CML, 30-50% of resistant cases are associated with additional chromosomal abnormalities. Nonrandom, extra Ph, trisomy 8 (+8), isochromosome 17 i (17q) and trisomy 19 (19+) are the most common secondary changes [present in approximately 13-34% of cases with additional abnormalities] (*Al-Dewik et al., 2014*).

These changes were referred to the, "major route" of CE, whereas other less frequently observed changes such as vanishing Y chromosome, trisomy 17 (+17), monosomy 7 (-7), 21, and deletion 17 (-17) occur in less than 10% and were designated as "minor route" aberrations (*Fabarius et al., 2011*).

Recent data suggest that there is a relation between these abnormalities and the blastic stage of chronic myeloid leukemia (*Luatti et al., 2012*).

AIM OF THE WORK

Few studies addressing the prognostic significance of ACAs in patients treated with TKIs have been published previously. We will search in this study for ACAs, specially i (17q), (whether present at diagnosis or acquired during treatment) in young adult Egyptian chronic myeloid leukemia patients and we will try to Determine their impact on patient outcome and response to TKI therapy

CHAPTER (1)

CHRONIC MYELOID LEUKEMIA

Disease Overview

Chronic myeloid leukemia (CML) is The classic chronic myeloproliferative disorder which is a clonal stem cell disorder, characterized by acquisition of an oncogenic BCR/ABL fusion protein as a result of a reciprocal translocation (9;22) (q34;q11) [the Philadelphia (Ph) chromosome] which leads to proliferation of granulocytic elements at all stages of differentiation (*Kaaren et al,2009*). This was initially depicted by John Hughes Bennett in 1845 at The Royal Infirmary of Edinburgh (*Quintás and Cortes, 2006*).

Chronic myeloid leukemia (CML) is said to be the malady of "firsts": 1) it is the first disease where the expression "leukemia" was used. 2) It is the first neoplastic disorder which was found to be connected with a recurrent chromosomal anomaly. 3) It is the first disease where targeted therapy against a fusion protein was used (*Buyukasik et al., 2010*).

Epidemiology:

CML frequency rates in western nations fluctuate from 0.6 to 2.0 cases for every 100,000 occupants (*Azzazi and Mattar, 2013*). The yearly frequency of CML in the United States is 1.0 to 1.3 per 100,000 individuals, which translated to approximately 5980 new cases in 2014. CML